Table 2.
Top Hits of Pathway Analysis
| Rank | Pathway | −log(p-value) | p value | corrected p value | Ratio | Genes |
|---|---|---|---|---|---|---|
| 1 | Neurophysiological process: Synaptic vesicle fusion and recycling in nerve terminals | 7.206 | 6.22E-08 | 2.69E-05 | 7/52 | PIPKI gamma, Synaptogamin I, Csp, SLC17A7, MUNC18, SYP, NSF |
| 2 | Neuroprotective action of lithium | 6.616 | 2.42E-07 | 5.23E-05 | 7/63 | PSD-95 (Dlg-4), MKK7 (MAP2K7), CDK5R1 (p25), CDK5R1 (p35), Dsh, ATF-2, Amyloid beta |
| 3 | Development_A1 receptor signaling | 5.78 | 1.66E-06 | 2.39E-04 | 6/53 | Adenosine A1 receptor, AKT (PKB), ATF-2, G-protein alpha-I family, PKA-cat, PKA-reg |
| 4 | Nicotine signaling in glutamatergic neurons | 5.53 | 2.95E-06 | 3.19E-04 | 5/33 | Adenosine A1 receptor, CaMK II alpha, G-protein alpha-I family, PKA-cat, PKA reg |
| 5 | Neurophysiological process_Constitutive and regulated NMDA receptor trafficking | 5.332 | 4.66E-06 | 4.02E-04 | 6/63 | CDK5R1 (p35), G-protein alpha-I family, PKA-cat, PKA-reg, PSD-95 (Dlg-4), SAP 102 (Dlg3) |
| 6 | Apoptosis and survival_BAD phosphorylation | 4.997 | 1.01E-05 | 7.00E-04 | 5/42 | 14-3-3, AKT (PKB), Bcl-XL, PKA-cat, PKA-reg |
| 7 | Development_A2A receptor signaling | 4.945 | 1.13E-05 | 7.00E-04 | 5/43 | AKT (PKB), ATF-2, MKK7 (MAP2K7), PKA-cat, PKA-reg |
| 8 | Apoptosis and survival Beta-2 adrenergic receptor anti-apoptotic action | 4.754 | 1.76E-05 | 8.49E-04 | 4/23 | AKT (PKB), G-protein alpha-I family, PKA-cat, PKA-reg |
| 9 | Development_Leptin signaling via PI3K-dependent pathway | 4.752 | 1.77E-05 | 8.49E-04 | 5/47 | AKT (PKB), AKT2, CPT-1A, PKA-cat, PKA-reg |
| 10 | Apoptosis and survival_HTR1A signaling | 4.619 | 2.40E-05 | 1.04E-03 | 5/50 | AKT (PKB), G-protein alpha-I family, PKA-cat, PKA-reg, PP2A regulatory |